Oric Pharmaceuticals, Inc. financial data

Symbol
ORIC on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1314% % -9.5%
Debt-to-equity 8.5% % -8.4%
Return On Equity -45% % -6.7%
Return On Assets -42% % -7.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 97,389,279 shares 38%
Common Stock, Shares, Outstanding 97,278,032 shares 38%
Entity Public Float $470,700,000 USD 14%
Common Stock, Value, Issued $11,000 USD 57%
Weighted Average Number of Shares Outstanding, Basic 98,953,331 shares 40%
Weighted Average Number of Shares Outstanding, Diluted 98,953,331 shares 40%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $32,091,000 USD 14%
Operating Income (Loss) $148,023,000 USD -9.8%
Nonoperating Income (Expense) $12,753,000 USD -14%
Net Income (Loss) Attributable to Parent $135,270,000 USD -13%
Earnings Per Share, Basic -1 USD/shares 3.3%
Earnings Per Share, Diluted -1 USD/shares 3.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $49,668,000 USD 12%
Assets, Current $295,594,000 USD 5.8%
Property, Plant and Equipment, Net $2,559,000 USD -17%
Operating Lease, Right-of-Use Asset $8,380,000 USD -8.4%
Other Assets, Noncurrent $7,131,000 USD -25%
Assets $431,192,000 USD 43%
Accounts Payable, Current $2,900,000 USD -32%
Accrued Liabilities, Current $17,279,000 USD 1.6%
Liabilities, Current $20,179,000 USD -5%
Operating Lease, Liability, Noncurrent $6,174,000 USD -17%
Other Liabilities, Noncurrent $4,094,000 USD -40%
Liabilities $24,273,000 USD -14%
Accumulated Other Comprehensive Income (Loss), Net of Tax $615,000 USD -15%
Retained Earnings (Accumulated Deficit) $661,737,000 USD -26%
Stockholders' Equity Attributable to Parent $406,919,000 USD 49%
Liabilities and Equity $431,192,000 USD 43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $32,533,000 USD -7.8%
Net Cash Provided by (Used in) Financing Activities $125,030,000 USD
Net Cash Provided by (Used in) Investing Activities $22,450,000 USD
Common Stock, Shares Authorized 1,000,000,000 shares 0%
Common Stock, Shares, Issued 97,278,032 shares 38%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10,072,000 USD -131%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $50,159,000 USD 12%
Deferred Tax Assets, Valuation Allowance $172,562,000 USD 30%
Deferred Tax Assets, Gross $175,149,000 USD 29%
Operating Lease, Liability $9,357,000 USD -8.4%
Depreciation $302,000 USD 16%
Payments to Acquire Property, Plant, and Equipment $387,000 USD 78%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $135,377,000 USD -14%
Lessee, Operating Lease, Liability, to be Paid $10,578,000 USD -12%
Property, Plant and Equipment, Gross $10,720,000 USD 4.1%
Operating Lease, Liability, Current $3,301,000 USD 5.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,455,000 USD 29%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,303,000 USD 16%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,221,000 USD -33%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,771,000 USD 3.5%
Deferred Tax Assets, Operating Loss Carryforwards $90,687,000 USD 20%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200,000,000 shares 0%
Unrecognized Tax Benefits $3,737,000 USD 33%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,049,000 USD -62%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $2,587,000 USD -3.4%
Share-based Payment Arrangement, Expense $23,962,000 USD 27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%